A Multicenter, Randomized, Controlled, Open-label, Group-Sequential, Phase III Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid Immune Globulin Infusion, 10 for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen�CD3?Directed Bispecific Antibody Therapy

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT06980480

Study #:
STUDY00161961

Start Date:
Dec 10, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06980480

View Complete Trial Details & Eligibility at ClinicalTrials.gov